Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.32 |
| ▸ | RELA | Q04206 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196196 | 0.84 | ESR1 (0.36) | ESR1ESR2NR1H2NR1H3NPC1 | |
| SCHEMBL198141 | 0.79 | ESR1 (0.54) | ESR1ESR2NR1H2NR1H3HPGD | |
| SCHEMBL197243 | 0.79 | NPC1 (0.34) | ESR1ESR2NPC1NFKB1RAB9A | |
| SCHEMBL12191039 | 0.78 | ESR1 (0.75) | ESR1ESR2NR1H2NR1H3HPGD | |
| SCHEMBL29935462 | 0.76 | CHRNB2 (0.34) | NR1H2NR1H3CHRNB2CHRNA4 | |
| SCHEMBL196394 | 0.76 | CHRNB2 (0.34) | NR1H2NR1H3CHRNB2CHRNA4 | |
| SCHEMBL15485716 | 0.76 | ESR1 (0.60) | ESR1ESR2NR1H2NR1H3HPGD | |
| SCHEMBL63526 | 0.75 | ESR1 (0.70) | ESR1ESR2NR1H2NR1H3HPGD | |
| Water SCHEMBL28099446 | 0.72 | ESR1 (0.67) | ESR1ESR2NR1H2NR1H3HPGD | |
| SCHEMBL27473457 | 0.72 | ESR1 (0.67) | ESR1ESR2NR1H2NR1H3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170054095-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2017-02-23 | — | — | US | disclosed |
| US-20170054095-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2017-02-23 | — | — | US | disclosed |
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | ESR1 871/4885ESR2 1656/4885NR1H2 3025/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | ESR1 997/4885ESR2 1520/4885NR1H2 2937/4885 |
| US-20170054095-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, LEF1, POU2F1 | ESR1 265/4885ESR2 775/4885NR1H2 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.